---

MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemia
Carlson HL, Nguyen TT, Tauchmann S, Carratt SA, Kruer TL, Dankyi NA, Balasis ME, Kim H, Tsai CF, Liu T, Shrestha SB, Fischer JM, Padron E, Braun TP, Maxson JE. MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemia. Blood Cancer Discov. 2026 Apr 19:10.1158/2643-3230.BCD-25-0446. doi: 10.1158/2643-3230.BCD-25-0446.

Mutant ASXL1 Drives Transcriptional Activation and Repression in Human Hematopoiesis
Madison L. Hall, Aliya Quintal, Samantha Worme, Thai Nguyen, Zachary Schonrock, Mitsuhiro Tsuchiya, Sonia N. Acharya, Hanqian L. Carlson, Itallia V. Pacentine, Shawn Shrestha, Jommel Macaraeg, Randall Armstrong, James McGann, Sara Evans-Dutson, Theresa A. Lusardi, Brendan L. O’Connell, Andrew C. Adey, Galip Gürkan Yardimci, Julia E. Maxson, Theodore P. Braun
bioRxiv 2026.01.13.699315; doi: https://doi.org/10.64898/2026.01.13.699315​

PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
William M Yashar, Itallia V Pacentine, Akram Taherinasab, Thai Nguyen, Samantha Worme, Mitsuhiro Tsuchiya, Theresa Lusardi, Chelsea Hutchinson, Thomas L Fillmore, Camilo Posso, Sara JC Gosline, Paul D Piehowski, Galip Gurkan Yardimci, Andrew C Adey, Julia E Maxson, Theodore P Braun
bioRxiv 2026.01.20.700677; doi: https://doi.org/10.64898/2026.01.20.700677

Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation
​Lucie Darmusey, Anna J. Bagley, Thai T. Nguyen, Hanqian L. Carlson, Hunter Blaylock, Shawn B. Shrestha, Amara Pang, Samantha Tauchmann, Sarah C. Taylor, Amy C. Foley, Katia E. Niño, Eric M. Pietras, Theodore P. Braun, Julia E. Maxson; Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation. Blood Adv 2025; 9 (7): 1593–1607. doi: https://doi.org/10.1182/bloodadvances.2024014362

Systematic benchmarking of single-cell ATAC-sequencing protocols
De Rop FV, Hulselmans G, Flerin C, Soler-Vila P, Rafels A, Christiaens V, González-Blas CB, Marchese D, Caratù G, Poovathingal S, Rozenblatt-Rosen O, Slyper M, Luo W, Muus C, Duarte F, Shrestha R, Bagdatli ST, Corces MR, Mamanova L, Knights A, Meyer KB, Mulqueen R, Taherinasab A, Maschmeyer P, Pezoldt J, Lambert CLG, Iglesias M, Najle SR, Dossani ZY, Martelotto LG, Burkett Z, Lebofsky R, Martin-Subero JI, Pillai S, Sebé-Pedrós A, Deplancke B, Teichmann SA, Ludwig LS, Braun TP, Adey AC, Greenleaf WJ, Buenrostro JD, Regev A, Aerts S, Heyn H. Nat Biotechnol. 2024 Jun;42(6):916-926.

Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic over Proliferative Subtype After Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review
Niehus HD, Sabile J, Maziarz RT, Meyers G, Cook R, Gandhi AP, Saultz JN, Rakshe S, Kaempf A, Braun T, Migdady Y. Acta Haematol. 2024 Jun 26. doi: 10.1159/000539880. Epub ahead of print.

CITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-Shiny. BMC Bioinformatics
Kong GL, Nguyen TT, Rosales WK, Panikar AD, Cheney JHW, Lusardi TA, Yashar WM, Curtiss BM, Carratt SA, Braun TP, Maxson JE. BMC Bioinformatics. 2024 Apr 2;25(1):142.

Predicting transcription factor activity using prior biological information
Yashar WM, Estabrook J, Holly HD, Somers J, Nikolova O, Babur Ö, Braun TP, Demir E. iScience. 2024 Feb 5;27(3):109124.

Multicancer Early Detection Tests: An Overview of Early Results From Prospective Clinical Studies and Opportunities for Oncologists
Post C, Braun TP, Etzioni R, Nabavizadeh N. JCO Oncol Pract. 2023 Dec;19(12):1111-1115.

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
Oyogoa E, Streich L, Raess PW, Braun T. Front Oncol. 2023 Sep 7;13:1217153.

Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Yashar W*, Smith BM*, Coleman DJ, VanCampen J, Kong G, Macaraeg J, Estabrook J, Demir E, Long N, Bottomly D, McWeeney SK, Tyner JW, Druker BJ, Maxson JE, Braun TP. Molecular Cancer Research. April 19, 2023.

ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II
​Braun TP, Estabrook, Coleman DJ, Schonrock Z, Smith BM, Enright T, Coblentz C, Callahan R, Mohammed H, Druker BJ, Lusardi TA, Maxson JE. Leukemia. December 16, 2022.

GoPeaks: histone modification peak calling for CUT&Tag
Yashar WY*, Kong G*, VanCampen J*, Curtiss BM*, Coleman DJ, Carbone L, Yardimci GG, Braun TP. BMC Genome Biology. July 4, 2022.

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
Smith BM, VanCampen J, Kong GL, Yashar W, Tsang YH, Horton W, Coleman DJ, Estabrook J, Lusardi TA, Mills GB, Druker BJ, Maxson JE, Braun TP. Leukemia. May 19, 2022.

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia
​Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. PNAS. May 20, 2020.

Response and Resistance to BCR-ABL1 Targeted Therapies
​Braun TP, Eide CA, Druker BJ. Cancer Cell. April 13, 2020

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia
Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, , Jeng S, Smith JL, Leonti AR, Ries RE, McWeeney S, Genua CD, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE. Nature Communications. November 29, 2019.

​Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE, Traer E. Leukemia Research Reports. December 25, 2014​.
​